AI Used to Replace Isoleucine in Dozens of Ribosomal Proteins in E. coli
Researchers used artificial intelligence to propose alternatives to the amino acid isoleucine in dozens of bacterial ribosome proteins. The work brings scientists closer to creating an organism that functions with fewer than 20 amino acids. Hundreds of amino acid types exist on Earth, yet all known life uses at least 20.
Scientists have partially eliminated the amino acid isoleucine from the bacterium Escherichia coli, an experiment in which isoleucine was replaced in dozens of ribosomal proteins. Of the hundreds of types of amino acids found on Earth, it remains a mystery why life settled on 20 as the building blocks for all its proteins.
Although certain species can use more, with some microbes employing up to 22, no organism has ever been found that uses fewer than 20 amino acids.
Researchers used AI to propose alternatives to the amino acid isoleucine in dozens of proteins that make up bacterial ribosomes. Ribosomes are the protein factories of the cell.
@ScienceMagazine reported that the findings offer a glimpse into how earlier, simpler life forms might have lived and suggest new ways to synthesize proteins with bespoke functions in medicine and biotechnology. The partial removal of isoleucine from E. Coli represents an advance toward understanding whether a simpler genetic code could have supported early life.
Key Facts
Story Timeline
2 events- 2026-05-15
Scientists partially eliminate isoleucine from E. coli using AI-proposed alternatives in ribosomal proteins
1 source@ScienceMagazine - Prior to 2026
No organism found using fewer than 20 amino acids despite hundreds of types existing on Earth
1 source@ScienceMagazine
Potential Impact
- 01
Potential new methods for synthesizing proteins with custom functions in medicine and biotechnology
- 02
Insights into possible simpler genetic codes of early life forms
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…